Chemical Radiosensitizers in Cancer Therapy

References

• Dewey D L. Effect of oxygen and nitric oxide on the radiosen-sitivity of human cells in tissue culture. Nature (Lond) 1960; 186: 780–782
   PubMed Web of Science ®Google Scholar
• Gray L H, Conger A D, Ebert M. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor of radiotherapy. Br J Radiol 1953; 26: 638–648
   PubMed Web of Science ®Google Scholar
• Thomlinson R H, Gray L H. The histological structure of some human lung cancer and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539–549
   PubMed Web of Science ®Google Scholar
• Brown J M. Evidence for acutely hypoxic cells in mouse tumors and a possible mechanism of reoxygenation. Br J Radiol 1979; 52: 650–655
   PubMed Web of Science ®Google Scholar
• Moulder J E, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10: 695–712
   PubMed Web of Science ®Google Scholar
• Cater D B, Silver I A. Quantitative measurements of oxygen tension in normal tissues and in the tumor of patients before and after radiotherapy. Acta Radiol 1960; 53: 233–256
   PubMed Web of Science ®Google Scholar
• Bush R S, Jenkin R DT, Allt W EC. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978; 37: 302–306, Suppl
   Web of Science ®Google Scholar
• Bush R S. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 1986; 12: 2047–2050
   PubMed Web of Science ®Google Scholar
• Brown J M. Sensitizers and protectors in radiotherapy. Cancer 1985; 55: 2222–2228
   PubMed Web of Science ®Google Scholar
• Dische S, Anderson P J, Sealy R. Carcinoma of the cervix–anaemia, radiotherapy and hyperbaric oxygen. Br J Radiol 1983; 56: 251–255
   PubMed Web of Science ®Google Scholar
• Bridges B A. Sensitization of organisms to radiation by sulfhy-dryl binding agents. Adv Radiat Biol 1969; 3: 123–176
   Google Scholar
• Djordjevic B, Szybalski W. Genetics of human cell lines III– incorporation of 5-bromo and 5-iododeoxyuridine into deoxyribonucleic acid and its effect on radiosensitivity. J Exp Med 1960; 112: 509–531
   PubMed Web of Science ®Google Scholar
• Szybalski W. Molecular events resulting in radiation injury, repair and sensitization of DNA. Radiat Res 1967; 147–159, (Suppl 7)
   Web of Science ®Google Scholar
• Shipley W V, Elkind M M, Prattler WB. Potentiation of X-ray killing by 5-bromodeoxyuridine in Chinese hamster cells–a reduction in capacity for sublethal damage accumulation. Radiat Res 1971; 47: 437–449
   PubMed Web of Science ®Google Scholar
• Kaplan H S. DNA strand scissions and the loss of viability after X-irradiation of normal and sensitized bacterial cells. Proc Natl Acad Sci USA 1966; 55: 1442–1446
   PubMed Web of Science ®Google Scholar
• Dewey D L, Humphrey R M. Increase in radiosensitivity of ionising radiation related to replacement of thymidine in mammalian cells with 5-bromodeoxyuridine. Radiat Res 1965; 26: 538–553
   PubMed Web of Science ®Google Scholar
• Kaplan H S, Smith K C, Tomlin P A. Effect of halogenated py-rimidines on radiosensitivity off. coli. Radiat Res 1962; 16: 98–113
   PubMed Web of Science ®Google Scholar
• Iliakis G, Kurtzman S, Pantelias G. Mechanism of radio-sensitization by halogenated pyrimidines: effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing. Radiat Res 1989; 119: 286–304
   PubMed Web of Science ®Google Scholar
• Adams G E. The general application of pulse radiolysis to current problems in radiobiology. Curr Top Radiat Res 1967; 3: 35–93
   Google Scholar
• Suit H D. Clinical and experimental radiotherapy. Textbook of Radiotherapy, GH Fletcher. Lea & Febiger, Philadelphia 1966; 556–558
   Google Scholar
• Goffinet D R, Brown J M. Comparison of intravenous and intraarterial pyrimidine infusion as a means of radiosensitizing tumors. Radiology 1977; 124: 819–822
   PubMed Web of Science ®Google Scholar
• Ensminger W D, Frei E. High dose intravenous and hepatic artery infusion of thymidine. Clin Pharmacol Ther 1978; 24: 610–615
   PubMed Web of Science ®Google Scholar
• Bagshaw M A, Dogget R L, Smith K C. Intra-arterial 5-bromodeoxyuridine and X-ray therapy. Am J Roentgenol 1967; 99: 886–894
   Web of Science ®Google Scholar
• Szybalski W. X-ray sensitization by halopyrimidines. Cancer Chemother Rep 1974; 58: 539–557
   PubMedGoogle Scholar
• Gratzner H G. Monoclonal antibody to 5-bromo and 5-iododeoxyuridine–a new reagent for detection of DNA replication. Science 1982; 218: 474–475
   PubMed Web of Science ®Google Scholar
• Russo A, Mitchell J, Kinsella T. Determinants of radiosensitivity. Semin Oncol 1985; 12: 332–349
   PubMed Web of Science ®Google Scholar
• Kinsella T J, Mitchell J B, Russo A. Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer. J Clin Oncol 1984; 2: 1144–1150
   PubMed Web of Science ®Google Scholar
• Kinsella T J, Russo A, Mitchell J B. A phase I study of intermittent intravenous BUdR with conventional irradiation. Int J Radiat Oncol Biol Phys 1984; 10: 69–76
   PubMed Web of Science ®Google Scholar
• Kinsella T J, Russo A, Mitchell J B. A phase I study of Shenoy and Singh intra-venous iododeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys 1985; 11: 1941–1946
   PubMed Web of Science ®Google Scholar
• Adams G E, Dewey D L. Hydrated electrons and radiobiological sensitization. Biochem Biophy Res Commun 1963; 12: 473–477
   PubMed Web of Science ®Google Scholar
• Bridges B A. Sensitization of Escherichia coli to gamma irradiation by N-ethyl maleimide. Nature (Lond) 1960; 188: 415
   Web of Science ®Google Scholar
• Adams G E, Cooke M S, Michael B D. Rapid mixing in radio-biology. Nature (Lond) 1968; 219: 1368–1369
   PubMed Web of Science ®Google Scholar
• Evans N TS, Naylor P FD. The effect of oxygen breathing and radiotherapy upon tissue oxygen tension of some human tumors. Br J Radiol 1963; 36: 418–425
   Web of Science ®Google Scholar
• Suit H D, Maeda M. Oxygen effect factor and tumor volume in C3H mouse mammary carcinoma–a preliminary report. Am J Roentgenol Radiat Ther Nucl Med 1966; 96: 177–182
   PubMed Web of Science ®Google Scholar
• Kallman R F, Jardine U, Johnson W. Effects of different schedules of dose fractionation on the oxygenation status of a transplantable mouse sarcoma. J Natl Cancer Inst 1970; 44: 369–377
   PubMed Web of Science ®Google Scholar
• Shank B, Chu F. Fractionation in radiotherapy: theoretical basis, experimental and clinical studies. Cancer Invest 1984; 2: 165–176
   PubMed Web of Science ®Google Scholar
• Churchill-Davidson I, Sanger C, Thomlinson R H. High pressure oxygen and radiotherapy. Lancet 1955; 2: 1091–1095
   Google Scholar
• Fowler J F. Chemical modifiers of radiosensitivity–theory and reality: a review. Int J Radiat Oncol Biol Phys 1985; 11: 665–674
   PubMed Web of Science ®Google Scholar
• Rockwell S. Use of perfluorochemical emulsion to improve oxygenation in a solid tumor. Int J Radiat Oncol Biol Phys 1985; 11: 97–103
   PubMed Web of Science ®Google Scholar
• Rockwell S, Mate T P, Irvin C G. Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of perfluorochemical emulsion. Int J Radiat Oncol Biol Phys 1986; 12: 1315–1318
   PubMed Web of Science ®Google Scholar
• Fischer J J, Rockwell S, Martin D E. Perfluorochemicals and hyperbaric oxygen in radiation therapy. Int J Radiat Oncol Biol Phys 1986; 12: 95–102
   PubMed Web of Science ®Google Scholar
• Rockwell S, Irvin C G, Kelly M. Preclinical studies of a perfluorochemical emulsion as an adjunct to radiotherapy. Int J Radiat Oncol Biol Phys 1988; 15: 913–920
   PubMed Web of Science ®Google Scholar
• Martin D F, Porter E A, Rockwell S. Enhancement of tumor radiation response by the combination of a perfluorochemical emulsion and hyperbaric oxygen. Int J Radiat Oncol Biol Phys 1987; 13: 747–751
   PubMed Web of Science ®Google Scholar
• Teicher B A, Holden S A, Crawford J M. Effects of Fluosol-DA and oxygen breathing on Adriamycin anti-tumor activity and cardiac toxicity in mice. Cancer Res 1988; 61: 2196–2201
   Google Scholar
• Teicher B A, Herman T S, Rose T M. Effect of Fluosol-DA on the response of intracranial 9L tumors to X-rays and BCNU. Int J Radiat Oncol Biol Phys 1988; 15: 1187–1192
   PubMed Web of Science ®Google Scholar
• Moulder J E, Fish B L. Intermittent use of a perfluorochemical emulsion (Fluosol-DA 20%) and carbogen breathing with fractionated irradiation. Int J Radiat Oncol Biol Phys 1988; 15: 1193–1196
   PubMed Web of Science ®Google Scholar
• Guichard M. Chemical manipulation of tissue oxygenation for therapeutic benefit. Int J Radiat Oncol Biol Phys 1989; 16: 1125–1130
   PubMed Web of Science ®Google Scholar
• Berry R J, Andrews J R. Quantitative studies of radiation effects on cell reproductive capacity in a mammalian transplantable tumor system in vivo. Ann NY Acad Sci 1961; 95: 1001–1008
   PubMed Web of Science ®Google Scholar
• Corgill D A. Arterial anti-cancer drug infusion therapy. Laryngoscope 1962; 72: 1158–1178
   PubMedGoogle Scholar
• Adams G E. Hypoxic radiosensitizers for radiotherapy. Int J Radiat Oncol Biol Phys 1978; 4: 135–141
   PubMed Web of Science ®Google Scholar
• McNally N J. The effect of a change in radiation quality on the ability of electron affinic sensitizers to sensitize hypoxic cells. Int J Radiat Biol 1976; 29: 191–196
   Web of Science ®Google Scholar
• Barnes J H, Ashwood-Smith M J, Bridges B A. Radiosensitization by carbonyl compounds. Int J Radiat Biol 1969; 15: 285–288
   Web of Science ®Google Scholar
• Adams G E, Cooke M S. Electron affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. Int J Radiat Biol 1969; 15: 457–471
   Web of Science ®Google Scholar
• Emmerson P T, Howard-Flanders P. Preferential sensitization of hypoxic bacteria to X-rays by organic nitroxide free radical. Radiat Res 1965; 26: 54–62
   PubMed Web of Science ®Google Scholar
• Emmerson P T. X-ray damage to DNA and loss of biological function–effects of sensitizing aspects. Adv Radiat Chem 1972; 3: 209–282
   Google Scholar
• Hewitt H B, Blake E R. Studies of the toxicity and radiosensi-tizing ability of triacetoneamine-/V-oxyl in mice. Br J Radiol 1970; 43: 91–96
   PubMedGoogle Scholar
• Cooke B C, Fielden E M, Johnson M. Polyfunctional radiosensitizers. I. Effects of a nitroxyl biradical on the survival of mammalian cells in vitro. Radiat Res 1977; 65: 152–162
   Web of Science ®Google Scholar
• Adams G E, Asquith J C, Dewey D L. Electron affinic sensitization. Part II. Para-nitroacetophenone: a radiosensitizer for anoxic bacteria and mammalian cells. Int J Radiat Biol 1971; 19: 575–585
   Web of Science ®Google Scholar
• Dugle D L, Chapman J D, Gillespie C J. Radiation induced strand breakage in mammalian cell DNA. I. Enhancement of single strand breaks by chemical radiosensitizers. Int J Radiat Biol 1972; 22: 545–555
   Web of Science ®Google Scholar
• Chapman J D, Webb R G, Borsa J. Radiosensitization of mammalian cells by p-nitroacetophenone. 1. Characterisation in asynchronous and synchronous populations. Int J Radiat Biol 1971; 19: 561–573
   Web of Science ®Google Scholar
• Reuvers A P, Chapman J D, Borsa J. Potential use of nitrofurans in radiotherapy. Nature (Lond) 1972; 237: 402–403
   PubMed Web of Science ®Google Scholar
• Watts M E. Radiosensitization of hypoxic cells by nitrofurans: dose modifying and shoulder effects. Int J Radiat Biol 1977; 31: 237–250
   Web of Science ®Google Scholar
• Rauth A M, Kaufman K. In vivo testing hypoxic sensitizers using KHT murine tumor assayed by the lung colony technique. Br J Radiol 1975; 48: 209–220
   PubMed Web of Science ®Google Scholar
• Denekamp J, Michael B D. Preferential sensitization of hypoxic cells to radiation in vivo. Nature (New Biol) 1972; 239: 21–23
   PubMedGoogle Scholar
• Foster J L, Willson R L. Radiosensitization of anoxic cells by metronidazole. Br J Radiol 1973; 46: 234–235
   PubMed Web of Science ®Google Scholar
• Asquith J C, Watts M E, Patel K. Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res 1974; 60: 108–118
   PubMed Web of Science ®Google Scholar
• Denekamp J, Michael B D, Harris S R. Hypoxic cell radiosensitizers–comparative tests of some electron affinic compounds in vivo. Radiat Res 1974; 60: 119–132
   PubMed Web of Science ®Google Scholar
• Begg A C, Sheldon P W, Foster J L. Demonstration of radiosensitization of hypoxic cells in solid tumors by misonidazole. Br J Radiol 1974; 47: 399–404
   PubMed Web of Science ®Google Scholar
• Stone H B, Withers H R. Tumor and normal tissue response to metronidazole and irradiation in mice. Radiology 1974; 113: 441–444
   PubMed Web of Science ®Google Scholar
• Peters L J. Modification of the radiocurability of a syngeneic murine squamous carcinoma by its site of growth by electron affinic drugs and ICRF-159. Br J Radiol 1976; 49: 708–715
   PubMed Web of Science ®Google Scholar
• Stone H B. Metronidazole and fractionated radiotherapy of a murine tumor. Int J Radiat Oncol Biol Phys 1976; 1: 1133–1137
   PubMed Web of Science ®Google Scholar
• Denekamp J, Stewart F A. Misonidazole sensitization of two mouse tumors to fractionated irradiation. Br J Cancer 1978; 37: 259–263, (Suppl III)
   Web of Science ®Google Scholar
• Mohindra J K, Rauth A M. Increased cell killing by metronidazole and nitrofurazone of hypoxic as compared to aerobic mammalian cells. Cancer Res 1976; 36: 930–936
   PubMed Web of Science ®Google Scholar
• Urtasun R C, Band P, Chapman J D. Radiation and high dose metronidazole in supratentorial glioblastomas. N Engl J Med 1976; 294: 1364–1367
   PubMed Web of Science ®Google Scholar
• Kapp D S, Wagner F C, Lawrence R. Glioblastoma multifor-mae–treatment by large dose fraction irradiation and metronidazole. Int J Radiat Oncol Biol Phys 1982; 8: 351–355
   PubMed Web of Science ®Google Scholar
• Wardman P. The use of nitro-aromatic compounds as hypoxic of radiosensitizers. Curr Top Radiat Res Q 1977; 11: 347–398
   PubMedGoogle Scholar
• Brown J M. Selective radiosensitization of the hypoxic cells of mouse tumors with nitroimidazoles. metronidazole and Ro-07–0582. Radiat Res 1975; 64: 633–647
   PubMed Web of Science ®Google Scholar
• Fowler J F, Adams G E, Denekamp J. Radiosensitizers of hypoxic cells in solid tumors. Cancer Treat Rev 1977; 3: 227–256
   Web of Science ®Google Scholar
• Sutherland R M. Selective chemotherapy of non-cycling cells in an in vitro tumor model. Cancer Res 1974; 34: 3501–3503
   PubMed Web of Science ®Google Scholar
• Brown J M. The mechanisms of cytotoxicity and chemosensi-tization by misonidazole and other nitroimidazoles. Int J Radiat Oncol Biol Phys 1982; 8: 675–682
   PubMed Web of Science ®Google Scholar
• Adams G E, Clarke E D, Gray P. Structure activity relationships in the development of hypoxic cell radiosensitizers. II. Cytotoxicity and therapeutic ratio. Int J Radiat Biol 1979; 35: 151–160
   Web of Science ®Google Scholar
• Mason R P, Holtzman J L. The role of catalytic superoxide formation in the 02 inhibition of nitro-reductase. Biochem Biophys Res Commun 1975; 67: 1267–1274
   PubMed Web of Science ®Google Scholar
• Verghese A J, Whitmore G F. Binding of nitro-reduction products of misonidazole to nucleic acids and proteins. Radiation Sensitizers: Their Use in Clinical Management of Cancer, LW Brady. Masson, New York 1980; 57–60
   Google Scholar
• Foster J L, Conroy P J, Searle A J. Metronidazole (Flagyl): characterization as a cytotoxic drug specific for hypoxic tumor cells. Br J Cancer 1976; 33: 485–490
   PubMed Web of Science ®Google Scholar
• Hendry J H, Sutton M L. Care with radiosensitizers. Br J Radiol 1980; 51: 927–928
   Web of Science ®Google Scholar
• Yuhas J M, Yurconic M, Kligerman M M. Combined use of radioprotective and radiosensitizing drugs in radiotherapy. Radiat Res 1977; 70: 433–443
   PubMed Web of Science ®Google Scholar
• Yu N Y, Brown J M. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR-2508. Int J Radiat Oncol Biol Phys 1984; 10: 1265–1269
   PubMed Web of Science ®Google Scholar
• Rojas A, Smith K A, Soranson J A. Enhancement of misonidazole radiosensitization by buthionine sulphoxamine. Ra-diother Oncol 1984; 2: 325–332
   PubMed Web of Science ®Google Scholar
• Fowler J F. Chemosensitization and radiosensitization by nitroimidazoles. New Chemo-and Radiosensitizing Drugs, A Breccia, JF Fowler. Bologna, La Scarebo 1985; 61–72
   Google Scholar
• Sheldon P W, Batten E L. Potentiation in vivo of melphalan activity by nitroimidazole compounds. Int J Radiat Oncol Biol Phys 1982; 8: 635–637
   PubMed Web of Science ®Google Scholar
• McNally N J. Enhancement of chemotherapy agents. Int J Radiat Oncol Biol Phys 1982; 8: 593–598
   PubMed Web of Science ®Google Scholar
• Thomlinson R H, Dische S, Gray A J. Clinical testing of the radiosensitizer Ro-07–0582 III: response of tumors. Clin Radiol 1976; 27: 167–174
   PubMed Web of Science ®Google Scholar
• Denekamp J, Fowler J F, Dische S. The proportion of hypoxic cells in a human tumor. Int J Radiat Oncol Biol Phys 1985; 2: 1227–1228
   Google Scholar
• Phillips T L, Wasserman T H. Promise of radiosensitizers and radioprotectors in the treatment of human cancer. Cancer Treat Rep 1984; 68: 291–302
   PubMedGoogle Scholar
• Urtasun R C, Coleman C N, Wasserman T H. Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward. Int J Radiat Oncol Biol Phys 1984; 10: 1692–1696
   Google Scholar
• Bartelink H, Bleehen N M, Phillips T L. Chemical modifiers. Int J Radiat Oncol Biol Phys 1988; 14: S39–S49
   PubMed Web of Science ®Google Scholar
• Sieman D W. Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys 1984; 10: 1585–1594
   PubMed Web of Science ®Google Scholar
• Mulcahy R T, Trump D L. Clinical chemosensitization by mi-sonidazole and related compounds. J Clin Oncol 1988; 6: 569–573
   PubMed Web of Science ®Google Scholar
• Adams G E, Ahmad I, Sheldon P W. RSU-1069: a 2-nitroimidazole containing an alkylating group. High efficiency as a radio-and chemosensitizer in vitro and in vivo. Int J Radiat Oncol Biol Phys 1984; 10: 1653–1656
   PubMed Web of Science ®Google Scholar
• Coleman C N, Wasserman T H, Phillips T L. Initial pharmacology and toxicology of intravenous desmethyl misonida-zole. Int J Radiat Oncol Biol Phys 1982; 8: 371–375
   PubMed Web of Science ®Google Scholar
• Dische S, Saunders M I, Stratford I J. Neurotoxicity of desmethyl misonidazole. Br J Radiol 1982; 54: 156
   Google Scholar
• Brown J M, Yu N Y, Brown D M. SR-2508: a 2-nitroimi-dazoleamide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys 1981; 7: 695–703
   PubMed Web of Science ®Google Scholar
• Smithen C E, Clark E D, Dale J A. Novel (nitro-1-imida-zolyl)-l alkanaloamines as potential radiosensitizers with improved therapeutic properties. Radiation Sensitizers–Their Use in Clinical Management of Cancer, LW Brady. Masson, New York 1980; 22–32
   Google Scholar
• Adams G E, Ahmad I, Sheldon P W. Radiation sensitization and chemopotentiation: RSU-1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer 1984; 49: 571–578
   PubMed Web of Science ®Google Scholar
• Fitzpatrick D A, Heindell N D, Egolf R A. Radiosensiti-zation of human colorectal tumor cells by 4-nitro-5-sulfona-toimidazoles. Radiat Res 1989; 117: 47–58
   PubMedGoogle Scholar
• Coleman C N. Hypoxic cell radiosensitizers: expectations and progress in drug development. Int J Radiat Oncol Biol Phys 1985; 11: 323–329
   PubMed Web of Science ®Google Scholar
• Curtiss S B, Tenforde T S, Afzal S MJ. Hypoxic cell sensitizers and heavy charged particle beams may play complimentary roles in killing hypoxic tumor cells. Int J Radiat Oncol Biol Phys 1984; 10: 1203–1205
   PubMed Web of Science ®Google Scholar
• Cater D B, Grigson C MB, Watkinson D A. Changes in oxygen tension in tumors induced by vaso-constrictor and vaso-dilator drugs. Acta Radiol 1962; 58: 401–408
   PubMed Web of Science ®Google Scholar
• Chaplin D J, Acker B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys 1987; 13: 579–585
   PubMed Web of Science ®Google Scholar
• Chaplin D J. Post-irradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers. Radiat Res 1988; 115: 292–302
   PubMed Web of Science ®Google Scholar
• Stratford I J, Adams G E, Godden J. Induction of tumor hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU-1069 in vivo. Int J Radiat Biol 1989; 55: 411–422
   PubMed Web of Science ®Google Scholar
• Horsman M R, Brown D M, Lemmon M J. Preferential tumor radiosensitization by analogs of nicotinamide and ben-zamide. Int J Radiat Oncol Biol Phys 1986; 12: 1307–1310
   PubMed Web of Science ®Google Scholar
• Horsman M R, Chaplin D J, Brown J M. Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res 1987; 109: 479–489
   PubMed Web of Science ®Google Scholar
• Horsman M R, Brown J M, Hirst V K. Mechanism of the action of the selective tumot radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys 1988; 15: 685–690
   PubMed Web of Science ®Google Scholar
• Alper T. Low oxygen enhancement ratios for radiosensitive bacterial strains and probable interactions of two types of primary lesions. Nature (Lond) 1968; 217: 862–863
   PubMed Web of Science ®Google Scholar
• Shenoy M A, Singh B B, Gopal-Ayengar A R. Iodine incorporated in cell constituents during sensitization to radiation by iodoacetic acid. Science 1968; 160: 999
   PubMed Web of Science ®Google Scholar
• Shenoy M A, Joshi D S, Singh B B. Role of membranes in radiation sensitization. Adv Biol Med Phys 1970; 13: 255–271
   PubMedGoogle Scholar
• Singh B B, Shenoy M A, Gopal-Ayengar A R. Iodination of Micrococcus radiodurans and inactivation of the repair system. Ind J Exp Biol 1971; 9: 518–519
   Web of Science ®Google Scholar
• Alper T. Cell death and its modification: the roles of primary lesions in DNA and membranes. Biophysical Aspects of Radiation Quality. IAEA, Vienna 1971; 171–184
   Google Scholar
• Shenoy M A, Asquith J C, Adams G E. Time resolved oxygen effects in irradiated bacteria and mammalian cells: a rapid-mix study. Radiat Res 1975; 62: 498–512
   PubMed Web of Science ®Google Scholar
• Seeman P. The membrane actions of anesthetics and tranquilizers. Pharmacol Rev 1972; 24: 583–655
   PubMed Web of Science ®Google Scholar
• Shenoy M A, Singh B B, Gopal-Ayengar A R. Enhancement of radiation lethality of E. coli B/r by procaine hydrochloride. Nature (Lond) 1974; 248: 415–416
   PubMed Web of Science ®Google Scholar
• George K C, Shenoy M A, Joshi D S. Modification of radiation effects on cells by membrane binding agents–procaine HC1. Br J Radiol 1975; 48: 611–614
   PubMed Web of Science ®Google Scholar
• Nair C KK, Pradhan D S. Effect of procaine hydrochloride on DNA repair in Escherichia coli. Chem-Biol Interact 1975; 11: 173–178
   PubMed Web of Science ®Google Scholar
• Yonei S. Inhibitory effect of membrane specific drugs on liquid holding recovery in UV irradiated E. coli cells. Int J Radiat Biol 1980; 37: 685–689
   Web of Science ®Google Scholar
• Shenoy M A, George K C, Srinivasan V T. Radiosensitization by membrane specific drugs. Modification of Radio-sensitivity of Biological Systems. IAEA, Vienna 1976; 131–140
   Google Scholar
• Djordjevic B. Differential effect of procaine on irradiated mammalian cells in culture. Radiology 1979; 131: 515–519
   PubMed Web of Science ®Google Scholar
• Yau T M. Procaine mediated modification of membranes and the response to X-irradiation and hyperthermia in mammalian cells. Radiat Res 1979; 80: 523–541
   PubMed Web of Science ®Google Scholar
• Yau T M, Kim S C. Local anaesthetics as hypoxic radiosensitizers, oxic radioprotectors and potentiators of hyperthermic killing of mammalian cells. Br J Radiol 1980; 53: 687–692
   PubMed Web of Science ®Google Scholar
• Mizuno S, Ishida A. Selective enhancement of bleomycin cytotoxicity by local anesthetics. Biochem Biophys Res Commun 1982; 105: 425–431
   PubMed Web of Science ®Google Scholar
• Komatsu K, Sakomoto K. Enhancement of the cytotoxic effects of pepleomycin by dibucaine. J Radiat Res 1985; 26: 426–435
   PubMed Web of Science ®Google Scholar
• Nicolson G L, Fidler I J, Poste G. Effects of tertiary amine local anaesthetics on blood-borne implantation and cell surface properties of metastatic melanoma cells. J Natl Cancer Inst 1986; 76: 511–519
   PubMed Web of Science ®Google Scholar
• Kessel D. Circumvention of resistance to anthracyclines by calcium anagonists and other membrane perturbing agents. Cancer Surv 1986; 5: 109–127
   PubMedGoogle Scholar
• Shenoy M A, George K C, Singh B B. Modification of radiation effects in single cell systems by membrane binding agents. Int J Radiat Biol 1975; 28: 519–526
   Web of Science ®Google Scholar
• Maniar H S, Singh B. B. Modification of radiation response of E. coli B/r cells by phenothiazines. Int J Radiat Biol 1983; 44: 399–404
   Web of Science ®Google Scholar
• Maniar H S, Nair C KK, Singh B B. Radioprotection of euoxic bacteria by phenothiazine drugs. Radiat Environ Biophys 1984; 23: 279–285
   PubMed Web of Science ®Google Scholar
• Shenoy M A, Gopalakrishna K. Biochemical aspects of radiosensitization of E. coli B/r by chlorpromazine. Int J Radiat Biol 1978; 33: 587–593
   Web of Science ®Google Scholar
• Shenoy M A, Biaglow J E, Varnes M E. A biochemical basis for the radiation and cytotoxic effects of chlorpromazine hydrochloride in vitro and in vivo. Int J Radiat Oncol Biol Phys 1982; 8: 725–728
   PubMed Web of Science ®Google Scholar
• Shenoy M A. Studies on radiation sensitization, cytotoxicity and potentiation of hyperthermic lethality by chlorpromazine. Seventh International Congress of Radiation Research, Amsterdam, 1983, Abstract D-6 52
   Google Scholar
• Schorn H, Bertsche U, Nusse M. The influence of membrane active drugs on the radiosensitivity of Ehrlich ascites tumor cells. Seventh International Congress of Radiation Research, Amsterdam, 1983, Abstract B-3 29
   Google Scholar
• Hait W N, Weiss B. Characteristics of the cyclic nucleotide phosphodiesterase of normal and leukaemic lymphocytes. Biochim Biophys Acta 1977; 497: 86–100
   PubMed Web of Science ®Google Scholar
• Maniar H S, Singh B B. Radiosensitizing and radioprotective effects of phenothiazines. Ind J Exp Biol 1985; 23: 100–102
   PubMed Web of Science ®Google Scholar
• Lehnert S. A comparative study of the cytotoxic and radiosensitizing effects of phenothiazines towards aerated and hypoxic mammalian cells. Seventh International Congress of Radiation Research, Amsterdam, 1983, Abstract B-6 20
   Google Scholar
• Shenoy M A, Singh B B. Phenothiazine induced radioprotection of normal mice–a preliminary report. Radiosens Newslett 1986; 5(2)3–4
   Google Scholar
• Shenoy M A, Singh B B. Hypoxic cytotoxicity of chlorpromazine and the modification of radiation response of E. coli B/r. Int J Radiat Biol 1978; 34: 595–600
   Web of Science ®Google Scholar
• Slater L M, Sweet P M, Stupecky M M. Albumin inhibition of anti-leukaemic activity of hydroxylated phenothiazines. Anti-Cancer Drug Design 1987; 1: 297–301
   PubMedGoogle Scholar
• Lehnert S. Cytotoxicity of phenothiazines: studies with aerated and hypoxic cells. Res Commun Chem Pathol Pharmacol 1987; 56: 361–374
   PubMedGoogle Scholar
• Shenoy M A, Singh B B. Temperature dependent modification of radiosensitivity following hypoxic cytocidal action of chlorpromazine. Radiat Environ Biophys 1985; 24: 113–117
   PubMed Web of Science ®Google Scholar
• Belkin M, Hardy W G. Effect of reserpine and chlorpromazine on Sarcoma 37. Science 1957; 125: 233–234
   PubMed Web of Science ®Google Scholar
• Gottileb L S, Hazel M, Broitman S. Effect of chlorpromazine on mouse mastocytoma. Fed Proc 1960; 19: 181
   Google Scholar
• Van Woert M H, Palmer S H. Inhibition of the growth of mouse melanoma by chlorpromazine. Cancer Res 1969; 29: 1952–1955
   PubMed Web of Science ®Google Scholar
• Chorazy M. Effect of chlorpromazine on Crocker sarcoma and Ehrlich ascites carcinoma. Nature (Lond) 1959; 184: 200–201
   Web of Science ®Google Scholar
• Cranston E M. Effect of some tranquilizers on a mammary adenocarcinoma. Cancer Res 1958; 18: 897–899
   PubMed Web of Science ®Google Scholar
• Lehnert S. In vivo toxicity of phenothiazines to cells of a transplantable tumor. Cancer Chemother Pharmacol 1986; 26: 269–272
   Google Scholar
• Cooper M, Mishima Y. Increase in in vitro radiosensitivity of malignant melanoma induced by in vivo administration of chlorpromazine. Br J Dermatol 1972; 86: 491–493
   PubMed Web of Science ®Google Scholar
• Damsker J I, Macklis R, Brady L W. Radiosensitization of malignant melanoma. I. The effect of 7-hydroxy chlorpromazine on the in vivo radiation response of Former's melanoma. Int J Radiat Oncol Biol Phys 1978; 4: 821–824
   PubMed Web of Science ®Google Scholar
• Shenoy M A, Singh B B. Cytotoxic and radiosensitizing effects of chlorpromazine hydrochloride in Sarcoma 180A. Ind J Exp Biol 1980; 18: 791–795
   PubMed Web of Science ®Google Scholar
• George K C, Srinivasan V T, Singh B B. Cytotoxic effect of chlorpromazine and its interaction with radiation on mouse fibrosarcoma. Int J Radiat Biol 1980; 38: 661–665
   Google Scholar
• George K C, Singh B B. Potentiation of radiation response of a mouse fibrosarcoma by phenothiazine drugs. Ind J Exp Biol 1984; 22: 305–307
   PubMed Web of Science ®Google Scholar
• Cohen M H. Enhancement of the antitumor effect of 1,3 bis (2-chloroethyl)-l-nitrosourea by chlorpromazine and caffeine. J Natl Cancer Inst 1973; 51: 1323–1325
   PubMed Web of Science ®Google Scholar
• Rose W C, Trader M W, Dykes D J. Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors. Cancer Treat Resp 1978; 62: 2085–2093
   Google Scholar
• Cohen M H, Schoenfeld D, Wolter J. Randomized trial of chlorpromazine, caffeine and methyl-CCNU in disseminated melanoma. Cancer Treat Rep 1980; 64: 151–153
   PubMedGoogle Scholar
• McKelvey E M, Luce J K, Vaitkevicius V K. W.s-Chlorethyl nitrosourea, vincristine, dimethyl triazenoimidazole carbox-amide (DTIC) and chlorpromazine combination chemotherapy in disseminated malignant melanoma. Cancer 1977; 39: 5–10
   PubMed Web of Science ®Google Scholar
• Hait W N, Lee G L. Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists. Biochem Pharmacol 1985; 22: 3973–3978
   Google Scholar
• Hait W N, Grais L, Benz C. Inhibition of the growth of leukaemic cells by inhibitors of calmodulin: phenothiazines and melittin. Cancer Chemother Pharmacol 1985; 14: 202–205
   PubMed Web of Science ®Google Scholar
• Abe K, Sekizawa T, Kogure K. Biophasic effect of chlorpromazine on cell viability in a neuroblastoma cell line. Neurosci Lett 1986; 71: 335–339
   PubMed Web of Science ®Google Scholar
• Mizuno S, Ishida A. Potentiation of bleomycin cytotoxicity by membrane interacting drugs and increased calcium ions. Biochem Biophys Res Commun 1982; 107: 1021–1027
   PubMed Web of Science ®Google Scholar
• Lazo J S, Chen D-L, Gallichio V S. Increased lethality of calmodulin antagonists and bleomycin to human bone marrow and bleomycin resistant malignant cells. Cancer Res 1986; 46: 2236–2240
   PubMed Web of Science ®Google Scholar
• Chafoulas J G, Bolton W E, Means A R. Potentiation of bleomycin lethality by anti-calmodulin drugs: a role for calmodulin in DNA repair. Science 1984; 224: 1346–1348
   PubMed Web of Science ®Google Scholar
• Hait W N, Lazo J S. Calmodulin–a potential target for cancer chemotherapeutic agents. J Clin Oncol 1986; 4: 994–1012
   PubMed Web of Science ®Google Scholar
• Lazo L S, Hait W N, Kennedy K A. Enhanced bleomycin induced DNA damage and cytotoxicity with calmodulin antagonists. Mol Pharmacol 1985; 27: 387–393
   PubMed Web of Science ®Google Scholar
• Hait W N, Glazer L, Kaiser C. Pharmacological properties of fluphenazine mustard, an irreversible calmodulin antagonists. Mol Pharmacol 1987; 32: 404–409
   PubMed Web of Science ®Google Scholar
• Hait W N, Lazo J S, Chen D L. Antitumor and toxic effects of combination chemotherapy with bleomycin and a phenothi-azine anticalmodulin agent. J Natl Cancer Inst 1988; 80: 246–250
   PubMed Web of Science ®Google Scholar
• Kaba K, Tani E, Morimura T. Potentiation of vincristine effect in human and murine glioma by calcium channel blockers or calmodulin inhibitors. J Neurosurg 1985; 63: 905–911
   PubMed Web of Science ®Google Scholar
• Klohs W D, Steinkampf R W, Havlick M J. Resistance to anthrapyrazoles and anthracyclines in multidrug resistant P-388 murine leukaemic cells: reversal by calcium blockers and calmodulin antagonists. Cancer Res 1986; 46: 4352–4356
   PubMed Web of Science ®Google Scholar
• Ganapathi R, Grabowski D, Schmidt H. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs. weak DNA binding antitumor drugs in doxorubicin resistant P-388 mouse leukaemia cells. Biochem Biophys Res Commun 1985; 131: 912–919
   PubMed Web of Science ®Google Scholar
• Ganapathi R, Grabowski D, Schmidt H. Factors governing the modulation of vinca alkaloid resistance in doxorubicin resistant cells by calmodulin inhibitor trifluoperazine. Biochem Pharmacol 1986; 35: 673–678
   PubMed Web of Science ®Google Scholar
• Akiyama S, Shiraishi N, Kurotomi Y. Circumvention of multiple drug resistance in human cancer cells by thioradazine, trifluoperazine and chlorpromazine. J Natl Cancer Inst 1986; 76: 839–844
   PubMed Web of Science ®Google Scholar
• Ganapathi R, Schmidt H, Grabowski D. Modulation of in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by calmodulin inhibitor trifluoperazine is dependent on the level of resistance. Br J Cancer 1988; 58: 335–340
   PubMed Web of Science ®Google Scholar
• Hait W N, DeRosa W T. Calmodulin as a target for new chemotherapeutic strategies. Clin Sci Rev 1988; 6: 499–511
   Google Scholar
• Wood P J, Hirst D G. Cinnarizine and flunarizine as radiation sensitizers in two murine tumors. Br J Cancer 1988; 58: 742–745
   PubMed Web of Science ®Google Scholar
• Wood P J, Hirst D G. Calcium antagonists as radiation modifiers: site specificity in relation to tumor response. Int J Radiat Oncol Biol Phys 1989; 16: 1141–1144
   PubMed Web of Science ®Google Scholar
• Sauter C. Do phenothiazines contribute to tumor regressions in lymphokine activated killer cells? Interleukin-2 treatment of renal cell cancer. Br J Cancer 1987; 56: 241–242
   PubMed Web of Science ®Google Scholar
• Peak M J, Pfaff M M, Periano C. Chlorpromazine ingestion inhibits UV-induced skin carcinogenesis. Photochem Photobiol 1987; 46: 1–4
   PubMed Web of Science ®Google Scholar
• Shenoy M A, Gopalakrishna K. Some mechanisms involved in the radiosensitization of E. coli B/r by paracetamol. Int J Radiat Biol 1977; 31: 577–587
   Web of Science ®Google Scholar
• Northover B J. Indomethacin–a calcium antagonist. Gen Pharmacol 1981; 8: 293–296
   Google Scholar
• Bennet A. Prostaglandins and cancer. Practical Applications of Prostaglandin and Their Synthesis Inhibitors, SMM Karim. University Park Press, Baltimore 1979; 149–188
   Google Scholar
• Famaey J-P, Whitehouse M W. Interaction between nonsteroidal anti-inflammatory drugs and biological membranes. IV. Biochem Pharmacol 1975; 24: 1609–1615
   PubMed Web of Science ®Google Scholar
• Shenoy M A, Singh B B. Studies on indomethacin as a potentiator for hyperthermic and radiation responses in a mouse fibrosarcoma. Cancer Lett 1989; 45: 227–232
   PubMed Web of Science ®Google Scholar
• Bruce A K, Malchman W H. Radiation sensitization of Micrococcus radiodurans, Sarcina lutea and Escherichia coli by p-hydroxymercuri-benzoate. Radiat Res 1965; 24: 473–481
   Web of Science ®Google Scholar
• Richmond R C, Powers E L. Modification of radiation sensitivity of bacterial spores by silver salts. Radiat Res 1974; 58: 470–480
   PubMed Web of Science ®Google Scholar
• Harris J W, Power J A. Diamide: a new radiosensitizer for anoxic cells. Radiat Res 1973; 56: 97–109
   PubMed Web of Science ®Google Scholar
• Harris J W, Power J A, Koch C J. Radiosensitization of hypoxic mammalian cells by diamide. I. Effects of experimental conditions on survival. Radiat Res 1975; 64: 270–280
   PubMed Web of Science ®Google Scholar
• Harris J W, Power J A, Koch C J. Synergistic chemical radiosensitization of hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1976; 1: 487–489
   PubMed Web of Science ®Google Scholar
• Watts M E, Whillans D W, Adams G E. Studies on the mechanisms of radiosensitization of bacterial and mammalian cells by diamide. Int J Radiat Biol 1975; 27: 259–270
   Web of Science ®Google Scholar
• Harris J W, Koch C J, Power J A. Radiosensitization of hypoxic mammalian cells by diamide. II. Studies on mechanism. Radiat Res 1977; 70: 585–596
   PubMed Web of Science ®Google Scholar
• Harris J W, Biaglow J E. Non-specific reactions of glutathione oxidant diamide with mammalian cells. Biochem Biophys Res Commun 1972; 46: 1743–1749
   PubMed Web of Science ®Google Scholar
• Harris J W. Cellular thiols in radiation and drug response. Radioprotectors and anti-carcinogens, OF Nygaard, MG Simic. Academic Press, New York 1983; 255–274
   Google Scholar
• Chapman J D, Reuvers A P, Borsa J. Chemical radiopro-tection and sensitization of mammalian cells growing in vitro. Radiat Res 1973; 56: 291–306
   PubMed Web of Science ®Google Scholar
• Kligerman M M, Schulhof L. Sensitization of bacteria to X-rays by neoarsphenamine. Radiat Res 1969; 39: 571–579
   PubMed Web of Science ®Google Scholar
• Kligerman M M, Lofgren S, Dean C. Sensitization of Micrococcus sodonensis to X-ray by neoarsphenamine in the presence of oxygen. Radiology 1967; 88: 993–994
   PubMed Web of Science ®Google Scholar
• Biaglow J E, Ferencz N, Friedell H L. A metabolic control for enhancement of radiation response. Am J Roentgenol Radiat Ther Nucl Med 1970; 107: 405–411
   Google Scholar
• Durand R E, Biaglow J E. Radiosensitization of hypoxic cells of an in vitro tumor model by respiratory inhibitors. Radiat Res 1977; 69: 359–366
   PubMed Web of Science ®Google Scholar
• Hetzel F W, Kaufman N. Chemotherapeutic drugs as indirect oxygen radiosensitizers. Int J Radiat Oncol Biol Phys 1983; 9: 751–757
   PubMed Web of Science ®Google Scholar
• Bushway A A, Whistler R L. Repression of cancer cell growth by 5-thio-D-glucose. J Carbohydrates Nucleosides Nucleotides 1975; 2: 399–405
   Google Scholar
• Song C W, Clement J J, Levitt S H. Preferential cytotoxicity of 5-thio-D-glucose against hypoxic tumor cells. J Natl Cancer Inst 1976; 57: 603–605
   PubMed Web of Science ®Google Scholar
• Song C W, Clement J J, Levitt S H. Elimination of hypoxic protection by 5-thio-D-glucose in multicell spheroids. Cancer Res 1978; 38: 4499–4503
   PubMed Web of Science ®Google Scholar
• Whistler R L, Lake W. Inhibition of cellular transport process by 5-thio-D-glucopyranose. Biochem J 1972; 130: 919–925
   PubMed Web of Science ®Google Scholar
• Tannock I F, Guttman P, Rauth A M. Failure of 2-deoxy-D glu-Chemical Radiosensitizers in Cancer Therapy cose and 5-thio-D-glucose to kill hypoxic cells in two murine tumors. Cancer Res 1983; 43: 980–983
   PubMedGoogle Scholar
• Rockwell S, Schulz R J. Failure of 5-thio-D-glucose to alter cell survival in irradiated or unirradiated EMT6 tumors. Radiat Res 1984; 100: 527–535
   PubMed Web of Science ®Google Scholar
• Jain V K, Pohlit W, Purohit S C. Influence of energy metabolism on the repair of X-ray damage in living cells. III. Effect of 2-deoxy-D-glucose on the liquid holding reactivation in yeast. Biophysik 1973; 10: 137–142
   PubMedGoogle Scholar
• Jain V R, Kalia V K, Gopinath P M. Optimization of cancer therapy. Part III. Effects of combining 2-deoxy-D-glucose treatment with gamma irradiation of normal mice. Ind J Exp Biol 1979; 17: 1320–1325
   PubMed Web of Science ®Google Scholar
• D'Angio G J, Farber S, Maddock C L. Potentiation of X-ray effects by actinomycin-D. Radiology 1959; 73: 175–177
   PubMed Web of Science ®Google Scholar
• Liebner E J. Actinomycin-D and radiation therapy. Am J Roentgenol 1962; 87: 94
   Web of Science ®Google Scholar
• Elkind M M, Whitmore G F, Alescio T. Actinomycin-D: Suppression of recovery in X-irradiated mammalian cells. Science 1964; 143: 1454–1457
   PubMed Web of Science ®Google Scholar
• Hellman S, Hannon E. Effects of Adriamycin on the radiation response of murine haemopoietic stem cells. Radiat Res 1976; 67: 162–167
   PubMed Web of Science ®Google Scholar
• Weinstein I B, Chernoff R, Finkelstein I. Miracil-D: an inhibitor of ribonucleic acid synthesis in Bacillus subtilis. Mol Pharmacol 1965; 1: 297–305
   PubMed Web of Science ®Google Scholar
• Bases R, Mendez E. Reversible inhibition of ribosomal RNA synthesis in HeLa cells by lucanthone (Miracil-D) with continued synthesis of DNA like RNA. J Cell Physiol 1969; 74: 283–294
   PubMed Web of Science ®Google Scholar
• Hirschberg F. Thioxanthenes: Miracil-D and hycanthone. Antibiotics, Vol 3, TW Corcoran, FE Hahn. Springer-Verlag, New York 1974; 274–303
   Google Scholar
• Brown D Q, Pittock J, Coia J. Radiosensitization of C3H mammary tumors using lucanthone and a medium dose rate. Radiat Res 1976; 67: 637, (abstract)
   Web of Science ®Google Scholar
• Turner S, Bases R, Pearlman A. The adjuvant effect of lucanthone (Miracil-D) in clinical radiation therapy. Radiology 1975; 124: 255–257
   Google Scholar
• Davies B MA, Watling D C. Radiosensitization of pulmonary metastases-I: in vivo testing of hycanthone, insulin and razox-ane. Int J Radiat Oncol Biol Phys 1979; 5: 803–809
   PubMed Web of Science ®Google Scholar
• Voiculetz N, Smith K C, Kaplan H S. Effect of quinacrine on survival and DNA repair in X-irradiated Chinese hamster cells. Cancer Res 1974; 34: 1038–1044
   PubMed Web of Science ®Google Scholar
• Kim S H, Kim J H, Fried J. Enhancement of radiation response of cultured tumor cells by chloroquine. Cancer 1973; 32: 536–540
   PubMed Web of Science ®Google Scholar
• Blackett N M, Wooliscroft W B, Fielden E M. Radiation modifying effect of the free radical norpseudopelletierine-Af-oxyl on normal bone marrow stem cells in vitro and in vivo. Radiat Res 1974; 58: 361–372
   PubMed Web of Science ®Google Scholar
• Millar B C, Fielden E M, Smithen C E. Polyfunctional radiosensitizers. III. Effect of the biradical (Ro-03–6061) in combination with other radiosensitizers on the survival of hypoxic V-79 cells. Radiat Res 1977; 69: 489–499
   PubMed Web of Science ®Google Scholar
• Millar B C, Fielden E M, Smithen C E. Polyfunctional radiosensitizers. IV. The effect of contact time and temperature on sensitization of hypoxic Chinese hamster cells in vitro by Afunctional nitroxyl compounds. Br J Cancer 1978; 37: 73–79, (Suppl III)
   Web of Science ®Google Scholar
• Ward J F. Mechanisms of DNA repair and their potential modification for radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12: 1027–1032
   PubMed Web of Science ®Google Scholar
• Weichselbaum R R. The role of DNA repair processes in the response of human tumors to fractionated radiotherapy. Int J Radiat Oncol Biol Phys 1984; 10: 1127–1134
   PubMed Web of Science ®Google Scholar
• Weichselbaum R R, Dahlberg W, Little J B. Inherently radioresistant cells exist in some human tumors. Proc Natl Acad Sci USA 1985; 82: 4732–4735
   PubMed Web of Science ®Google Scholar
• Weichselbaum R R, Little J B. The differential response of human tumors to fractionated radiation may be due to a post-irradiation repair process. Br J Cancer 1982; 46: 532–537
   PubMed Web of Science ®Google Scholar
• Nakatsugawa S, Sugahara T. Inhibition of X-ray induced potentially lethal damage (PLD) repair by cordycepin (3-deoxy-adenosine) and enhancement of its action by 2-deoxyformycin in Chinese hamster hair cells in stationary phase in vitro. Radiat Res 1980; 84: 265–275
   PubMed Web of Science ®Google Scholar
• Nakatsugawa S, Kumar A, Sugahara T. Purine nucleoside analogues inhibit the repair of radiation induced potentially lethal damage in mammalian cells in culture. Int J Radiat Biol 1982; 41: 343–346
   Web of Science ®Google Scholar
• Nakatsugawa S, Kada T, Nikaedo O. PLDR inhibitors: their biological and clinical implications. Br J Cancer 1984; 49: 43–47, (Suppl VI)
   PubMed Web of Science ®Google Scholar
• Weichselbaum R R, Dahlberg W, Beckett M. Radiation resistant and repair proficient human tumor cells may be associated with radiotherapy failure in head and neck cancer patients. Proc Natl Acad Sci USA 1986; 83: 2684–2688
   PubMed Web of Science ®Google Scholar
• McNally N J. Book review. Br J Radiol 1985; 58: 580
   Google Scholar
• Schwartz J L, Rotmensch J, Giovanazzi S. Faster repair of DNA double strand breaks in radioresistant human tumor lines. Int J Radiat Oncol Biol Phys 1988; 15: 907–912
   PubMed Web of Science ®Google Scholar
• Brown J M. Hypoxic cell sensitizers: what next. Int J Radiat Oncol Biol Phys 1989; 16: 987–993
   PubMed Web of Science ®Google Scholar
• Singh B B. Radiosensitization. Atomic Energy Rev 1980; 18: 171–222
   Google Scholar
• Shenoy M A, Singh B B. Non-nitro radiation sensitizers. Int J Radiat Biol 1985; 48: 315–326
   Web of Science ®Google Scholar
• Jacobs G P. Non-nitro radiation sensitizers. Int J Radiat Biol 1986; 49: 887–890
   Web of Science ®Google Scholar